Follicular lymphoma is a form of non-Hodgkin lymphoma. It’s usually slow-growing and responds well to treatment but is difficult to cure. Since it is a slow-moving cancer, doctors and patients ...

Follicular lymphoma is a typically slow-progressing B-cell lymphoproliferative disease that originates from transformed follicular center B cells. It is commonly marked by widespread lymph node ...

Lymphoma Research Foundation and Follicular Lymphoma Innovation (IFLI) announce major investment to host 2026 International Scientific Workshop to advance research and innovation in follicular ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Although follicular lymphoma usually can't be cured, you can live long and well with it. This cancer grows slowly. You may not need treatment for many years, or ever.

For patients with relapsed or refractory follicular lymphoma, Monjuvi (tafasitamab-cxix) in addition to Revlimid (lenalidomide) and Rituxan (rituximab) led to a 57% reduction in the risk of disease ...

There have been a number of advancements in the treatment of follicular lymphoma in 2024. In March, the Food and Drug Administration (FDA) approved Brukinsa (zanubrutinib) plus Gazyva (obinutuzumab) ...

Analyzing over 40,000 lymphoma patients This population-based study included 44,127 patients with follicular lymphoma from the SEER database, 6569 of which had a subsequent malignancy.

These results and results from the TRIANGLE trial put “the nail in the coffin” on across-the-board use of ASCT, Tycel Phillips, MD, of City of Hope in Duarte, California, said in an interview.

Adverse Events Treatment-emergent adverse events (TEAEs) were 99% in both arms, with balance between grade 3 and 4 AEs (71% vs 69%), but slightly higher for tafasitamab. The most common grade 3 or ...

But if your follicular lymphoma is resistant to treatment or comes back, your team may consider mosunetuzumab (Lunsumio) as a combination CD20-antibody and CD3 T-cell treatment.

The Food and Drug Administration (FDA) has granted accelerated approval to Epkinly ® (epcoritamab-bysp) for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL ...